Insud Pharma S.L.U. entered into a definitive agreement to acquire Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS) on October 1, 2023. Definitive agreements for Active Pharmaceutical Ingredients (API) and Women's Healthcare business reflect gross proceeds of up to approximately $1.2 billion. The transaction is subject to regulatory approvals. The transaction is expected to close in Q1 2024. As of November 8, 2023 the transactions are expected to close by the end of the first half of 2024. As of February 28, 2024, transaction is expected to close by the end of the first quarter of 2024. Viatris intends to prioritize the use of net proceeds from the divestitures for debt paydown. Mark I. Greene, Aaron M. Gruber, Andrew M. Wark, J. Leonard Teti II, Kiran Sheffrin, Jonathan J. Katz, David J. Kappos, Margaret T. Segall, Nicole M. Peles, Matthew Morreale, Joyce Law, Brian M. Budnick and Anthony J. Grisafi of Cravath, Swaine & Moore LLP and Mohit Saraf, Bikash Jhawar, Nipun Vaid, Akshayy S Nanda, Sahil Arora, Amit Gupta and Akshay Jain of Saraf & Partners acted as legal advisors, PricewaterhouseCoopers LLP acted as an accountant and Jefferies International Limited acted as a financial advisor to Viatris.

Insud Pharma S.L.U. completed the acquisition of Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS) on March 12, 2024.